Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PCSK9 drugs
Biotech
Merck dives into data showing PCSK9 pill easily outswims rivals
Merck lifted the lid on the third positive phase 3 trial of its PCSK9 inhibitor, showing the edge the asset has over other oral non-statin therapies.
Nick Paul Taylor
Mar 30, 2026 11:45am
Merck's PCSK9 drug mounts injectable-like cholesterol reductions
Nov 10, 2025 10:59am
Merck's oral PCSK9 makes waves with 3rd phase 3 win
Sep 2, 2025 9:35am
Merck's oral PCSK9 inhibitor leader reduces cholesterol in ph. 3
Jun 9, 2025 9:00am
Verve posts clean PCSK9 editor profile, teeing up Lilly decision
Apr 14, 2025 7:00am
Verve halts VERVE-101 enrollment, focuses on 2nd PCSK9 editor
Apr 2, 2024 7:00am
